1057671-58-5 Usage
General Description
3-(4-difluoromethoxy-phenyl)-propan-1-ol is a compound with the chemical formula C10H13F2O2. It is an organic compound that is composed of a phenyl group with a difluoromethoxy substituent attached to the third carbon of a propan-1-ol chain. 3-(4-difluoromethoxy-phenyl)-propan-1-ol is commonly used in medicinal and pharmaceutical applications as a building block for the synthesis of various pharmaceutical drugs and compounds. It is also used in research and development for its unique chemical properties and potential pharmacological activity. Additionally, 3-(4-difluoromethoxy-phenyl)-propan-1-ol may be used in organic synthesis and as a reagent in chemical reactions.
Check Digit Verification of cas no
The CAS Registry Mumber 1057671-58-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,5,7,6,7 and 1 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1057671-58:
(9*1)+(8*0)+(7*5)+(6*7)+(5*6)+(4*7)+(3*1)+(2*5)+(1*8)=165
165 % 10 = 5
So 1057671-58-5 is a valid CAS Registry Number.
1057671-58-5Relevant articles and documents
Structure-activity relationship studies and sleep-promoting activity of novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 2
Sifferlen, Thierry,Koberstein, Ralf,Cottreel, Emmanuelle,Boller, Amandine,Weller, Thomas,Gatfield, John,Brisbare-Roch, Catherine,Jenck, Francois,Boss, Christoph
, p. 3857 - 3863 (2013/07/27)
Replacement of the dimethoxyphenyl moiety in the core skeleton of almorexant by appropriately substituted imidazoles afforded novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as potent dual orexin receptor antagonists. We describe in th
5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS
-
Page/Page column 42, (2010/01/30)
The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5- a]pyrazine derivatives of formula (I) wherein R1, R2, R3, and R4 are as described n the description, to salts, especially pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments; especially as orexin receptor antagonists.
